[
  {
    "ts": "2026-02-26T02:48:02+00:00",
    "headline": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product […]",
    "url": "https://finance.yahoo.com/news/rbc-capital-sees-merck-mrk-024802301.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ddc15b55-286c-390a-99a1-282359ccf6d7",
      "content": {
        "id": "ddc15b55-286c-390a-99a1-282359ccf6d7",
        "contentType": "STORY",
        "title": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product […]",
        "pubDate": "2026-02-26T02:48:02Z",
        "displayTime": "2026-02-26T02:48:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-sees-merck-mrk-024802301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-sees-merck-mrk-024802301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T11:33:00+00:00",
    "headline": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
    "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
    "url": "https://finance.yahoo.com/news/immunoassay-neurological-biomarkers-market-research-113300382.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f7a1f95e-c51b-3242-82ec-d494f2a78e27",
      "content": {
        "id": "f7a1f95e-c51b-3242-82ec-d494f2a78e27",
        "contentType": "STORY",
        "title": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
        "description": "",
        "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
        "pubDate": "2026-02-26T11:33:00Z",
        "displayTime": "2026-02-26T11:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/59bfa81aab40cd840b8e3b01728763d8",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Immunoassay for Neurological Biomarkers Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lTmZWZHAJ.pTE.8k1c6auQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/59bfa81aab40cd840b8e3b01728763d8.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qbj2WDpPGTETsT_qIwyIrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/59bfa81aab40cd840b8e3b01728763d8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immunoassay-neurological-biomarkers-market-research-113300382.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immunoassay-neurological-biomarkers-market-research-113300382.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "QGEN"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T12:39:00+00:00",
    "headline": "For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.",
    "summary": "“Botox on steroids”: Old hair-loss drugs are getting an upgrade, and new ones are on the way.",
    "url": "https://www.marketwatch.com/story/for-the-first-time-in-decades-new-hair-loss-treatments-are-in-the-works-heres-how-theyre-different-c2033ade",
    "source": "MarketWatch",
    "provider": "yfinance",
    "raw": {
      "id": "f6c03342-8396-39a2-aa8f-ef7ce49dc0aa",
      "content": {
        "id": "f6c03342-8396-39a2-aa8f-ef7ce49dc0aa",
        "contentType": "STORY",
        "title": "For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.",
        "description": "",
        "summary": "“Botox on steroids”: Old hair-loss drugs are getting an upgrade, and new ones are on the way.",
        "pubDate": "2026-02-26T12:39:00Z",
        "displayTime": "2026-02-26T12:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketwatch_hosted_869/4a8f30306a6b65d2f7e786c09e361e6c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AppT2t.EUN1xXVzZUidB_w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch_hosted_869/4a8f30306a6b65d2f7e786c09e361e6c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2NeG39rioDGPCpB5A3VEsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketwatch_hosted_869/4a8f30306a6b65d2f7e786c09e361e6c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketWatch",
          "url": "http://www.marketwatch.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketwatch.com/story/for-the-first-time-in-decades-new-hair-loss-treatments-are-in-the-works-heres-how-theyre-different-c2033ade",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/first-time-decades-hair-loss-123900984.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MANE"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-26T13:00:00+00:00",
    "headline": "Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer",
    "summary": "MENLO PARK, Calif., February 26, 2026--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ong",
    "url": "https://finance.yahoo.com/news/synthekine-announces-clinical-trial-collaboration-130000083.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b50fd3ac-c25a-3d83-87c2-148f0caba740",
      "content": {
        "id": "b50fd3ac-c25a-3d83-87c2-148f0caba740",
        "contentType": "STORY",
        "title": "Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer",
        "description": "",
        "summary": "MENLO PARK, Calif., February 26, 2026--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ong",
        "pubDate": "2026-02-26T13:00:00Z",
        "displayTime": "2026-02-26T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4",
          "originalWidth": 2412,
          "originalHeight": 503,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LNo3Cym6ENlK9nx261Vxfw--~B/aD01MDM7dz0yNDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4.cf.webp",
              "width": 2412,
              "height": 503,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rHwsdiP5GxA3.KVzWjpmyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cc52becf79c9b28bb2e4836135d949a4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/synthekine-announces-clinical-trial-collaboration-130000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/synthekine-announces-clinical-trial-collaboration-130000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]